A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology

Europace

Volumn 11, Issue 4, 2009, Pages 458-464

  Arya, Anita ^a   Silberbauer, John ^a   Teichman, Sam L ^b   Milner, Peter ^b   Sulke, Neil ^a   Camm, A John ^c  

^a EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b ARYx Therapeutics   (United States)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Amiodarone analogue; ATI 2042; Atrial fibrillation; Efficacy; Pacemaker diagnostics; Pacemakers; Paroxysmal atrial fibrillation; Safety

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATI 2042; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; NAUSEA; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZOFURANS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65249171943     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun384     Document Type: Article

References (31)

1. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
2. Vrobel TR, Miller PE, Mostow ND, Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31: 393-426.
3. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993;72:45F-50F.
4. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100z:2025-34.
5. Staubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H et al. Pharmaco-kinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 1985;29:417-23.
6. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122: 689-700.
7. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
8. Juhasz A, Bodor N. Cardiovascular studies on different classes of soft drugs. Pharmazie 2000;55:228-38.
9. Morey TE, Seubert CN, Raatikainen MJ, Martynyuk AE, Druzgala P, Milner P et al. Structure - activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther 2001; 297:260-6.
10. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al. Amiodarone to prevent the recurrence of atrial fibrillation. N Engl J Med 2000;342:913-20.
11. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
12. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
13. Waldo A, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF et al. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
14. Brendorp B, Pederson OD, Torp-Pederson C, Sahebzadah N, Køber L. A benefit - risk assessment of class III antiarrhythmic agents. Drug Saf 2002;25: 847-65.
15. Castro L, Mialet-Perez J, Guillemeau A, Stillitano F, Zolk O, Eschenhagen T et al. Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J Mol Cell Cardiol 2005;39:335-44.
16. Kober L, Bloch Thomsen PE, Møller M, Torp-Pedersen C, Carlsen J, Sandøe E et al. Effect of dofetilide in patients with recent myocardial infarction or left ventricular dysfunction: a randomised trial. Lancet 2000;356:2052-8.
17. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation and flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 2000;102: 2385-90.
18. Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 2005;23:217-30.
19. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Efficacy and dose-response. J Am Coll Cardiol 2000;36:794-802.
20. Roy D, Rowe BH, Stiell IG, Coutu D, Ip JH, Phaneuf D et al. A randomised controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61.
21. Gillis AM. Rhythm control in atrial fibrillation: endpoints for device based trials. Heart Rhythm 2004;1:B52-7, discussion.
22. Rose MS, Gillis A, Sheldon RS. Evaluation of bias in using the time to first event when the inter-event intervals have a Weibull's distribution. Stat Med 1999;18: 139-54.
23. Greer GS, Wilkinson WE, McCarthy EA, Pritchett EL. Random and nonrandom behaviour of symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1989;64:339-42.
24. Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation following DDDR pacemaker implantation. Am J Cardiol 2000;85:1445- 50.
25. Shehadeh LA, Liebovitch LS, Wood MA. Temporal patterns of atrial arrhythmia recurrences in patients with implantable defibrillators: implications for assessing implantable defibrillators. J Cardiovasc Electrophysiol 2002;13:303-9.
26. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett LC. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89:224- 7.
27. Pritchett EL, Hammill SC, Reiter MJ, Lee KL, McCarthy EA, Zimmerman JM et al. Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia. Am J Cardiol 1983;52:1007-12.
28. Silberbauer J, Arya A, Freemantle N, Paul V, Patel NR, Lloyd GW et al. The relationship between atrial lead type and the accuracy of arrhythmia discrimination? Heart 2006;92 (Suppl. 2):A36.
29. Silberbauer J, Boodhoo L, Arya A, Freemantle N, Smith DH, O'Nunain S et al. The Pacemaker Atrial Fibrillation Study (PAFS): the effect of anti-AF pacing algorithms in patients with paroxysmal atrial fibrillation. Heart 2006;92(Suppl. 2):A84.
30. Carlioz R, Perrier E, Thomas O, Fossati F, Jarwe M, Klug D et al. Accuracy of atrial tachyarrhythmia monitoring in the selection device: correlation with external Holter recording. Europace 2000;2(Suppl. D):9-10.
31. Purerfellner H, Gillis A, Holbrook R, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004;27:983-92.